Relationship between breast cancer and increased prolactin hormone levels and TSH levels in menopausal and pre-menopausal women: A Case-Control Study

Document Type : Original Article


1 Instructor, Department of Anesthesia, Research Center for social Determinants of Health, School of Nursing, Jahrom University of Medical Sciences, Jahrom, Iran.

2 Assistant Professor, Department of Obstetrics and Gynecology, Women’s Health and Disease Research Center, Faculty of Medicine, Jahrom University of Medical Sciences, Jahrom, Iran.

3 General practitioner, Student Research Committee, Faculty of Medicine, Jahrom University of Medical Sciences, Jahrom, Iran.

4 Assistant Professor, Department of Pharmacology, Women's Health and Disease Research Center, Faculty of Medicine, Jahrom University of Medical Sciences, Jahrom, Iran.


Introduction: Despite many promising advances in recent years, our standing about the onset, progression, and metastasis of breast cancer is not yet complete. However, it is believed that hormones in women may also play an import role in the onset and progression of breast cancer. Therefore, this study was performed with aim to investigate the relationship between prolactin level and breast cancer in menopausal and pre-menopausal women.
Methods: This case-control study was conducted on 100 women with breast cancer referred to Breast Cancer Center of Peymanieh Hospital (Jahrom University of Medical Sciences) in two groups of breast cancer (25 menopausal and 25 pre-menopausal women) and control group (25 menopausal and 25 pre-menopausal women) in 2018. Serum prolactin levels were measured by ELISA and malondialdehyde method manually and by reaction with thiobarbituric acid. Data were analyzed using SPSS software (version 21) and Chi-square and Mann-Whitney tests. P<0.05 was considered statistically significant.
Results: Two groups were homogeneous in terms of mean of age, weight, height, duration of marriage, time of first delivery and number of offspring (p >0.05). There was no significant relationship between increased prolactin level and breast cancer in menopausal women (p = 0.425). There was no significant relationship between increased prolactin hormone and breast cancer in pre-menopausal women (p = 0.867). There was no significant difference between menopausal women with breast cancer and control group in the frequency of TSH (p = 0.378).
Conclusion: There was no significant relationship between increased prolactin hormone and breast cancer in menopausal and pre-menopausal women. However, elevated serum levels of TSH were more common among those with breast cancer than healthy controls, but the difference was not significant. However, further investigation is needed in this regard.


  1. Boyle P, Levin B. World Cancer Report 2008. International Agency for Research on Cancer (IARC), Geneva; 2008.
  2. World Health Organization. Breast cancer: prevention and control. 2013. Available at: er/en/. Accessed May 7, 2013.
  3. Abbasalipourkabir R, Salehzadeh A, Abdullah R. Cytotoxicity effect of solid lipid nanoparticles on human breast cancer cell lines. Biotechnology 2011; 10(6):528-533.
  4. Tikk K, Sookthai D, Johnson T, Rinaldi S, Romieu I, Tjønneland A, et al. Circulating prolactin and breast cancer risk among pre-and postmenopausal women in the EPIC cohort. Ann Oncol 2014; 25(7):1422-8.
  5. Center for Disease Management, Non-Communicable Disease, Cancer Management. National Cancer Registry Report 2003. Kalk Publications. Summer 2005. [In Persian].
  6. Fichtner I, Becker M, Zeisig R, Sommer A. In vivo models for endocrine-dependent breast carsivoma: special consideration of clinical relevance.  European Journal of Cancer 2004; 40(6):845-51.
  7. Miller AB. An Overview of Hormone-associated Cancer. Cancer Res 1978; 38(11pt2):3985-90.
  8. Holdaway IM, Friesen HG. Hormone binding by human mammary carcinoma. Cancer Res 1997; 37(7pt1):1946-52.
  9. Nandi S. Role of hormones in mammary neoplasia. Cancer Res 1978; 38(11 Pt 2):4046-9.
  10. McGuire WL. Steroid receptor in human breast cancer. Cancer Res 1978; 38(11pt2):4289-91.
  11. Mujagic Z, Srabovic N, Mujagic M. The role of prolactin in human breast cancer. BiochemiaMedica. 2009;19(3): 236-249.
  12. Tworoger SS, Rice MS, Rosner BA, Feeney YB, Clevenger CV, Hankinson SE. Bioactive prolactin levels and risk of breast cancer: a nested case–control study. Cancer Epidemiol Biomarkers Prev 2015; 24(1):73-80.
  13. Faupel-Badger JM, Sherman ME, Garcia-Closas M, Gaudet MM, Falk RT, Andaya A, et al. Prolactin serum levels and breast cancer: relationships with risk factors and tumour characteristics among pre- and postmenopausal women in a population-based case-control study from Poland. Br J Cancer 2010; 103(7):1097-102.
  14. Wang DY, De Stavola BL, Bulbrook RD, Allen DS, Kwa HG, Fentiman IS, et al. Relationship of blood prolactin levels and the risk of subsequent breast cancer. Int J Epidemiol 1992; 21(2):214-21.
  15. Taghiyar S, Shahanipoor K, Razmi NA. Comparison of the Serum Level of Carcinoembryonic antigen, Prolactin, and Malondialdehyde in Patients Suffering from Breast Cancer and in Healthy individuals in Isfahan. J Fasa Univ Med Sci 2014; 4(3):362-370.
  16. Aliasgarzadeh A, Sanaat Z, Karimi Avval S, Niafar M, Agamohammadzadeh N. Thyroid Autoimmunity in Patients with Breast Cancer. Iranian Journal of Endocrinology and Metabolism 2011; 13(2):190-196.
  17. Maruchi N, Annegers JF, Kurland LT. Hashimoto’s thyroiditis and breast cancer. Mayo Clin Proc 1976; 51(5):263-5.
  18. Gogas J, Kouskos E, Tseleni-Balafouta S, Markopoulos C, Revenas K, Gogas G, et al. Autoimmune thyroid disease in women with breast carcinoma. Eur J Surg Oncol 2001; 27(7):626-30.
  19. Gutzman JH, Miller KK, Schuler LA. Endogenous human prolactin and not exogenous human prolactin induces estrogen receptor alpha and prolactin receptor expression and increases estrogen responsiveness in breast cancer cells. J Steroid Biochem Mol Biol 2004; 88(1):69-77.
  20. Wang M, Wu X, Chai F, Zhang Y, Jiang J. Plasma prolactin and breast cancer risk: a meta-analysis. Sci Rep 2016; 6:25998.
  21. Gill S, Peston D, Vonderhaar BK, Shousha S. Expression of prolactin receptors in normal, benign,and malignant breast tissue: an immunohistological study. J Clin Pathol 2001; 54(12):956-60.
  22. Ormandy CJ, Hall RE, Manning DL, Robertson JF, Blamey RW, Kelly PA, et al. Coexpression and cross-regulation of the prolactin receptor and sex steroid hormone receptors in breast cancer. J Clin Endocrinol Metab 1997; 82(11):3692-9.
  23. Rae-Venter B, Nemoto T, Schneider SL, Dao TL. Prolactin binding by human mammary carcinoma: Relationship to estrogen receptor protein concentration and patient age. Breast Cancer Res Treat 1981; 1(3):233-43.
  24. McTiernan A, Wu L, Chen C, Chlebowski R, Mossavar-Rahmani Y, Modugno F, et al. Relation of BMI and physical activity to sex hormones in postmenopausal women. Obesity (Silver Spring) 2006; 14(9):1662-77.
  25. Katz TA, Wu AH, Stanczyk FZ, Wang R, Koh WP, Yuan JM, et al. Determinants of prolactin in postmenopausal Chinese women in Singapore. Cancer Causes Control 2018; 29(1):51-62.
  26. Espinosa de los Monteros A, Cornejo J, Parra A. Differential prolactin response to oral metoclopramide in nulliparous versus parous women throughout the menstrual cycle. Fertil Steril 1991; 55(5):885-9.
  27. Musey VC, Collins DC, Musey PI, Martino-Saltzman D, Preedy JR. Long-term effect of a first pregnancy on the secretion of prolactin. N Engl J Med 1987; 316(5):229-34.